A great round of drug launches is underway in the Danish pharmaceutical group Novo Nordisk. One of those drugs is the long-acting diabetes drug Tresiba, a project that is headed by 46-year-old Jakob Riis.
He has transformed the marketing function in Novo Nordisk, so his department for Global Marketing and Medical Affairs is now a central part of Novo Nordisk’s commercial function, according to Berlingske Business.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app